Soluleaves Launch in the UK

RNS Number:8438X
BioProgress PLC
06 June 2007


For Immediate Release                                             6 June 2007



              BioProgress launch first SoluleavesTM products in UK



London, UK, 5th June 2007: BioProgress plc ('BioProgress' or the 'Company')
(AIM: BPRG; NASDAQ: BPRG), the specialty pharmaceutical and healthcare company,
is pleased to announce the launch in the UK of the first of its range of
SoluleavesTM, melt in the mouth products.



The first two SoluleavesTM products to be marketed will be, Caffeine Soluleaves
TM - energy boost, and Zinc and Echinacea, which helps boost natural defences
against colds and flu.  Other SoluleavesTM products including Vitamin B complex
and anti-snoring will be launched in the coming weeks.



The SoluleavesTM range of products will be marketed through the newly acquired
PharmaHerb Limited, a specialist Over The Counter (OTC) products company, using
the Kudos brand. Distribution will be through its established niche health
shops, pharmacies, supermarket chains, as well as its direct to consumer
internet selling (www.kudosvitamins.com).



The market for energy products in the UK is valued around #700m, with the UK
cough cold market valued at #430m. The company believes the products possess a
number of advantages over existing market products such as being quick to
disperse in the mouth leading to rapid onset of action, and suitable for people
who have difficulty swallowing tablets and capsules. Peak sales are estimated to
be within 1 to 1.5% of their appropriate market.



Richard Trevillion, Chief Executive Officer, of BioProgress commented:

"It is testament to the strength and depth of the Company's infrastructure that
BioProgress has been able to reformulate to UK standards and launch new products
in record time. This launch has been timed to capitalize upon the recent
acquisition of PharmaHerb. It will also be the first time consumers will have
access to the benefits of the SoluleavesTM system in the UK market".











For further information:


BioProgress Plc                                   + 44 (0) 20 7098 9881
Richard Trevillion, CEO
Steve Martin, CDO
Hiral Patel, CFO

Buchanan Communications                           + 44 (0) 20 7466 5000
Rebecca Skye Dietrich
Mark Court





About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company
has over 80 patents granted or in application within 24 patent families and has
product development agreements and strategic alliances with several global
companies. As a virtually integrated business, BioProgress has acquired sales
and marketing resources within Europe and the US as a launch mechanism for its
own pharmaceutical products. The business continues to develop innovative
delivery mechanisms using its XGELTM polymer technology, replacing the need to
use animal-derived gelatine in pharmaceutical and healthcare products. For
further information please go to www.bioprogress.com



Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934.  To the extent that this announcement contains certain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995, this paragraph applies.  These statements are
based on management's current expectations and are subject to uncertainty and
changes in circumstances.  Actual results may vary materially from the
expectations contained in the forward-looking statements.  The forward-looking
statements in this release include statements addressing future financial and
operating results and the timing and benefits of the reorganisation.  Detailed
information about factors pertinent to the business of the company that could
cause actual results to differ is set forth in the Company's filings with the
Securities and Exchange Commission.  The Company is under no obligation to (and
expressly disclaim any such obligation to) update or alter its forward-looking
statements whether as a result of new information, future events or otherwise.
This announcement is for information only and does not constitute an offer or
invitation to acquire or dispose of any securities or investment advice.  The
distribution of the announcement and/or issue of securities in certain
jurisdictions may be restricted by law.  Persons into whose possession this
announcement comes are required to inform themselves about and to observe such
restrictions.












                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

PRLOKAKNKBKKKAK